Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,145 JPY | +0.48% | -13.84% | +1.78% |
May. 08 | Japanese Shares Swing to Red Amid Profit-Taking, US Rate Cut Uncertainty | MT |
May. 08 | Kissei Pharmaceutical's Attributable Profit Jumps 6% in Fiscal 2023; Shares Tumble 11% | MT |
Strengths
- The company returns high margins, thereby supporting business profitability.
- The company appears to be poorly valued given its net asset value.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.78% | 886M | - | ||
+7.22% | 72.5B | A | ||
+14.11% | 9.11B | A- | ||
-11.75% | 5.07B | A- | ||
+59.61% | 5.01B | - | ||
+2.62% | 3.85B | B- | ||
-17.54% | 2.46B | C- | ||
+21.35% | 2.44B | B | ||
-27.82% | 2.26B | - | ||
+25.13% | 2.27B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4547 Stock
- Ratings Kissei Pharmaceutical Co., Ltd.